32 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
27 Oct 22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
4:20pm
, advance multiple pivotal studies across thalassemia, sickle cell disease and pediatric pyruvate kinase deficiency, and build a sustainable pipeline
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
5 May 22
Agios Reports Business Highlights and First Quarter 2022 Financial Results
7:21am
and Governance (ESG) Report disclosing ESG initiatives and metrics aligned with the United Nations Sustainable Development Goals (UN SDGs) and the standards
8-K
EX-99.1
71fgjnk
2 Apr 21
Agios Announces Closing of Oncology Business Sale to Servier
4:47pm
DEFM14A
x8imsihxa2 61tz
11 Feb 21
Proxy related to merger
4:19pm
PREM14A
him1u1az6ftet ny
29 Jan 21
Preliminary proxy related to merger
4:22pm
DEFA14A
aptg881g4
12 Jan 21
Additional proxy soliciting materials
5:15pm
DEFA14A
0cr2wq0ynu9rc
11 Jan 21
Additional proxy soliciting materials
7:17am
8-K
EX-99.1
9wxnukai60ytn6
11 Jan 21
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
7:14am
DEFA14A
saq1 e8tq
21 Dec 20
Additional proxy soliciting materials
5:23pm
DEFA14A
EX-99.1
518bf1mhdh8k4f
21 Dec 20
Additional proxy soliciting materials
7:10am
DEFA14A
EX-99.2
xwvpgqz
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.1
c9n4ogita3 fmudgre
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.2
07om rprz0
21 Dec 20
Regulation FD Disclosure
7:04am